JP3475332B2 - Chemical evaporator for long-term transpiration - Google Patents

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a long-time evaporative chemical vaporizer for evaporating various chemical agents by heating.

[0002]

2. Description of the Related Art Conventionally, as a heat evaporation preparation, a method of heat evaporating a solid, liquid or pasty medicine using a heating element is known, and a typical example thereof is It is an electric mosquito trap. The electric mosquito repellent is an insecticidal mat containing a drug placed on a heating plate that is electrically heated to evaporate the drug and is used for insecticidal purposes. Further, a base material such as a fiberboard mainly composed of pulp or asbestos, which holds a chemical, is used.

In this type of heating and vaporization device represented by an electric mosquito trap, since it is heated and used for a long time,
The problem is how to control the decomposition and evaporation rate of the drug component to stably evaporate the drug for a long time. Various compounds are conventionally known as sustained-release agents for controlling transpiration of drug components, and examples thereof include piperonyl butoxide, pyrethroid insecticides, paraffins, olive oil, and oils and fats such as peanut oil. Water-added oils,
Alternatively, it has been considered to add a repellent such as diethyltoluamide or a kind of surfactants to make it sustained-release. On the other hand, as a method for suppressing the decomposition of the active ingredient, it is generally known to blend an antioxidant, and it is disclosed in JP-A-53-12.
1927 discloses various effective antioxidants. However, even if such a measure is taken, the residual rate of the active ingredient after heating and use is high, and a problem still remains in terms of sufficient effective use of the active ingredient.

That is, in the conventional heating evaporation device, since the mat containing the chemical is directly placed on the heating plate to heat it, the entire mat is always kept in a high temperature state more than necessary and comes into contact with the heating plate. The active ingredient evaporates not only from the surface of the mat, but also from the top of the mat. Therefore, the amount of the volatilized drug in the initial stage of heating is large, and thereafter, the amount of volatilized drug is remarkably reduced, stable evaporation cannot be obtained over a long period of time, the efficacy is decreased accordingly, and the residual ratio of the drug is increased.

Further, when the temperature distribution of the heat generating plate is observed in detail, generally the surface temperature of the heat generating plate is not uniform, and there is a difference in surface temperature between the central portion and the peripheral portion. For example, the surface temperature of the central portion of the heat generating plate is When the temperature is 170 ° C, the surface temperature of the peripheral portion is about 130 ° C. As a result, local heating of the central part of the mat occurs, which causes thermal decomposition of the active ingredient, and causes a decrease in drug evaporation efficiency and a decrease in efficacy. Further, in the conventional heat generating plate, since the surface temperature is not uniform as described above, the amount of chemical evaporation from the corresponding portion of the mat that contacts the central portion having a high surface temperature is large, and the concentration of the chemical in that portion is extremely dilute. . Therefore, most of the chemicals move to the central portion of the lower surface of the mat and evaporate. In this case, the chemicals need to move in the vertical and horizontal directions of the mat, and the moving distance becomes long, so that the chemical evaporation This is one of the factors that make it difficult to smoothly supply the drug and thus to stably evaporate the drug. Further, since the evaporation of the drug is concentrated in that portion, thermal decomposition of the drug is likely to occur, and a clogging phenomenon occurs, which hinders smooth evaporation of the drug thereafter.

[0006] Therefore, an object of the present invention is to solve the above problems in heat evaporation of a drug and to provide a means capable of stably and effectively evaporating the drug over a long period of time. A further object of the present invention is to uniformly heat the heating element side of the drug-containing body in which the drug is applied and impregnated during heating and evaporation of the drug, and suppress thermal decomposition of the drug and deterioration such as clogging of the drug-containing body, which is effective. It is intended to provide a means which has a high volatilization rate and can stably evaporate a drug over a long period of time. Still another object of the present invention is to provide a drug vaporizer which is safe for children, without directly touching the drug during handling.

[0007]

According to the present invention, in order to achieve the above-mentioned object, a long length mounted on a heating element is used.
A synthetic tree having an opening in a chemical vaporizer for time transpiration
Molded container made of fat and containing drug held inside the container
A drug vaporizer consisting of the body and the top and bottom plates of the container
A plurality of protrusions are provided on at least one outer surface of the
And / or the inner surface of at least one of the top plate and bottom plate of the container
A plurality of ribs for carrying the drug-containing body are projected on the surface,
Drugs so that the distance between the agent-containing body and the heating element is 1 mm or more
Long-term, characterized in that the agent-containing body is supported by the container
A chemical vaporizer for intertranspiration is provided.

[0008]

EFFECTS OF THE INVENTION According to the present invention, unlike the conventional insecticidal mat, in which the base material containing the drug is heated in direct contact with the heating element, it is made of synthetic resin having an opening. A long-time evaporative chemical vaporizer, which holds the drug-containing body inside the molding container, is placed on a heating element, and the container bottom plate under the drug-containing element and / or the drug-containing element and the heating element are used. It is configured to indirectly heat the drug-containing body through a space existing between and. Here, unlike a molded container made of a synthetic resin molded container, even if an external force is applied to the container, unlike a flexible bag-shaped container, the spatial positional relationship with the drug-containing body does not change inside. The term “made of synthetic resin” means that materials having high thermal conductivity, such as metals, are positively excluded. Further, the long-time evaporative body for evaporating apparatus refers to an evaporative body for a transpiration device of a type that slowly evaporates over at least 12 hours (half a day). According to the present invention, the drug-containing body and the heating element are kept at a constant distance, and the bottom plate of the container and / or the space below the drug-containing body form a so-called soaking part. The lower surface temperature of the drug-containing body can be set to a substantially uniform temperature which is considerably lower than the maximum temperature of the surface of the heating element, and the lower surface of the drug-containing body can be heated uniformly. As a result, when viewed microscopically, the upper part of the drug-containing body is kept at a lower temperature than the lower part, so that the drug mainly evaporates evenly from the lower surface of the drug-containing body, and the opening of the container is closed. After that, it is volatilized to the outside. As the drug evaporates, the drug moves from the upper part to the lower part of the drug-containing body, that is, from the high concentration region of the drug to the low concentration region,
Since the distance of drug transfer at this time is the shortest and the transfer is in the direction according to gravity, it is possible to transfer the drug very smoothly, and the drug is supplied just enough to evaporate the drug, ensuring stable drug evaporation. It can be carried out.

Further, the so-called soaking section described above is formed between the drug-containing body and the heating element to prevent a rapid temperature rise or local heating of the lower surface of the drug-containing body during heating after mounting on the heating device. Therefore, thermal decomposition of the drug can be suppressed. Even during the use period, the drug contained in the upper part of the drug-containing body is kept at a temperature lower than the lower surface heating temperature, so that the drug is less thermally decomposed, and the evaporation surface of the drug-containing body is clogged. It is possible to suppress deterioration of the chemicals, etc., and to obtain stable chemical vaporization with a high effective volatilization rate. Further, as in the present invention, the long-time evaporative drug vaporizer has a structure in which the drug-containing body is held inside a synthetic resin molded container, so that the handling is performed by holding the container (the drug-containing drug ) Is safe because there is no need to touch it directly, especially for children with weak skin and can prevent accidental ingestion.
Furthermore, it is strong against impacts and the like and is advantageous in terms of drug protection.

[0010]

DETAILED DESCRIPTION OF THE INVENTION The drug-containing body used in the present invention is a porous body containing various inorganic substances and / or organic substances and having various pores, and containing various drugs. As the inorganic substance and / or the organic substance as the base material of the drug-containing body,
Various substances can be used, for example, clay, talc, kaolin, diatomaceous earth, gypsum, perlite, bentonite, acid clay, volcanic rock, calcium carbonate, magnesium carbonate, sodium hydrogen carbonate, calcium phosphate, calcium hydrogen phosphate, anhydrous phosphoric acid. Calcium hydrogen, calcium lactate, aluminum silicate, magnesium silicate, colloidal silica, lactose, sucrose, starch, CM
C, MC, hydroxypropyl starch, magnesium hydroxide aluminate, magnesium aluminometasilicate,
Examples thereof include polymer resins such as glass fiber, rock wool, sepiolite, clay, coke, graphite, wood powder, cellulose, pulp, linter, polyethylene, polypropylene, polyphenylene sulphite, and polyamide, but they are naturally limited to these. It is not something that will be done. These are formed as a fibrous material into a mat, or one or more of inorganic powder and / or organic powder is extrusion-molded together with a binder and dried, or one or more of inorganic powder and / or organic powder as they are. It can be molded by a method such as compression molding, or compression molding with the addition of a binder, and the above-mentioned material being fired.

As the binder, various cellulose derivatives such as CMC, MC and hydroxyethyl cellulose, gelatin, gum arabic, polyvinyl alcohol (PV
A), starch and its derivatives, pullulan, casein and its derivatives, alginic acid and its derivatives, curdlan, agar, carrageenan, julan gum, succinoglucan, furceleran, karaya gum, acacia gum, tamarind gum, acrylamide polymer, tragacanth gum, dextran. , Albumin, soy protein, polyvinyl ether, polyethyleneimine, nigeran, rutin acid, phosphorus mannan, levan, pectin, polyvinylpyrrolidone, collagen, polyvinylmethacrylate,
Various thickeners such as sodium chondroitin sulfate, water-soluble polymers, polysulfone (PS), polyphenylsulfone, polyphenylene sulfite (PPS), polyvinyl butyral (PVB), acrylic resin, polyamide (PA), polypropylene ( PP), polyethylene (PE), ethylene vinyl acetate copolymer (EVA), phenol resin, melamine resin, urea resin, tar,
Pitch, urethane, wax, wax emulsion,
Examples of the colloidal silica, magnesium metasilicate aluminate, water glass, aluminum phosphate, sodium phosphate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, and the like can be exemplified, but are not particularly limited thereto. .

The drug-containing body may contain a solvent, a pigment, a dye, a preservative, if necessary, within a range that does not impair the characteristics of the drug-containing body.
Other additives such as other fixing agents, antioxidants, ultraviolet absorbers, water / oil resistance improvers, fragrances, flame retardants and strength improvers may be added. Examples of antioxidants that can be added include 3,5-di-t-butyl-4-hydroxytoluene and 3
-T-butyl-4-hydroxyanisole, 3,5-di-t-butyl-4-hydroxyanisole, mercaptobenzimidazole, dilauryl-thio-di-propionate, 2-t-butyl-4-methoxyphenol, 3
-T-butyl-4-methoxyphenol, 2,6-di-
t-butyl-4-ethylphenol, stearyl-β-
(3,5-di-t-butyl-4-hydroxyphenyl)
Propionate, α-tocopherol, ascorbic acid, erythorbic acid, 2,2′-methylene-bis (6-
t-butyl-4-methylphenol), 2,2'-methylene-bis- (6-t-butyl-4-ethylphenol), 4,4'-methylene-bis (2,6-di-t-butylphenol) ), 4,4'-butylidene-bis (6-
t-butyl-3-methylphenol), 4,4'-thio-bis (6-t-butyl-3-methylphenol),
1,1-bis (4-hydroxyphenyl) cyclohexane, 1,3,5-trimethyl-2,4,6-tris (3,5-di-t-butyl-4-hydroxybenzyl)
Benzene, tris (2-methyl-4-hydroxy-5-
t-butylphenyl) butane, tetrakis [methylene (3,5-di-t-butyl-4-hydroxyhydrocinnamate)] methane, octadecyl-3,5-di-t-
Butyl-4-hydroxyhydrocinnamate, phenyl-β-naphthylamine, N, N-diphenyl-p-phenylenediamine, 2,2,4-trimethyl-1,3-dihydroquinoline polymer, 6-ethoxy-2,2,2. 4-
Trimethyl-1,3-dihydroquinoline, 3,5-di-
t-Butyl-4-hydroxy-benzylphosphonate-diethyl ester, bis (3,5-di-t-butyl-4-hydroxybenzylphosphonate ethyl) calcium: polyethylene wax, octylated diphenylamine, tris [2- ( 3 ', 5'-di-t-butyl-4'
-Hydroxyhydro-cinnamoyloxyl) ethyl]
Isocyanurate, tris- (4-t-butyl-2,6)
-Dimethyl-3-hydroxybenzyl) isocyanurate, 3,9-bis [1,1-di-methyl-2- {β-
(3-t-Butyl-4-hydroxy-5-methyl-phenyl) propionyloxy} ethyl] -2,4,8,1
0-tetraoxaspiro [5,5] undecane, ditridecyl-3,3'-thiodipropionate, dimyristyl-3,3'-thiodipropionate, distearyl-
3,3'-thiodipropionate, triethylene glycol-bis [3- (3-t-butyl-5-methyl-4-
Hydroxyphenyl) propionate], 1,6-hexanediol-bis [3- (3,5-di-t-butyl-
4-Hydroxyphenyl) propionate], N, N '
-Hexamethylenebis (3,5-di-t-butyl-4-
Hydroxy-hydrocinnamamide), 2,2-thio-diethylenebis [3- (3,5-di-t-butyl-4-hydroxyphenyl) propionate], N, N'-bis [3- (3,3 5-di-t-butyl-4-hydroxyphenyl) propionyl] hydrazine, tris- (3,5-
Di-t-butyl-4-hydroxybenzyl) -isocyanurate and 2,4-bis- (n-octylthio) -6
Examples thereof include compounds such as-(4-hydroxy-3,5-di-t-butylanilino) -1,3,5-triazine. These compounds may be used alone or in combination of two or more. Addition of these antioxidants provides effects such as prevention of thermal deterioration during heating, prevention of oxidation, decomposition of chemicals, prevention of polymerization, and improvement of long-term stability over time.

Further, antioxidants generally called peroxide decomposers such as dilauryl thiodipropionate (DLTP) and distearyl thiodipropionate (D
STP) and the like may be used in combination with the antioxidant. Further, by using an ultraviolet absorber as a stabilizer, the light resistance during storage and use can be further improved.

Various transpiration agents can be contained in the drug-containing body of the present invention. As the insecticide, various conventionally used transpiration agents can be used. Pyrethroid insecticides, Carbamate insecticides, organophosphorus insecticides and the like can be mentioned. Generally, a pyrethroid insecticide is preferably used because it is highly safe, and examples thereof include allethrin, dl, d-T80-allethrin, d, d.
-T80-allethrin, d, d-T80-praletrin, phthalthrin, d-T80-resmethrin, d-T
80-flamethrin, permethrin, phenothrin, fenvalerate, cypermethrin, cyphenothrin, empentrin, terraresulin, etofenprox,
Various conventionally known pyrethroid insecticides such as hemfluthrin and benfluthrin can be used. In addition, heat-transpiration bactericides, acaricides, antifungal agents, rust preventives, aromatic agents, repellents and the like can be used as chemicals.

The material for the container holding the drug-containing body is desired to have heat resistance and chemical resistance depending on the drug used. For example, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, polyacetal, melamine resin, polytetrafluoroethylene, phenol resin, unsaturated polyester resin, epoxy resin, urethane resin, methacrylic acid resin, polyarylate, Examples thereof include polyketone, polyamideimide, polyallyl sulfone, polyphenylene sulfite, polyphenyl sulfone, and polyether nitrile. The shape of the container is not limited to a substantially rectangular parallelepiped, a substantially columnar shape, a substantially elliptical shape, a substantially polygonal column,
And their frustum shape are arbitrary. Further, the shape of the drug-containing body can be formed into any shape corresponding to the shape of these containers. The container is formed by a usual molding method, and examples thereof include injection molding, pressure molding and compression molding. Furthermore, the container wall and / or the drug-containing body can be formed into a porous shape. As a heating method of a heating element on which a drug vaporizer holding a drug-containing body is placed inside such a container, a method of energizing a heater using a resistance heater (such as a nichrome wire) and a semiconductor (PTC), Oxidation reaction (oxidation of metals such as iron and magnesium), water reaction (reaction of raw coal and water, etc.),
A method of using combustion heat of alcohol, gas, kerosene, wax, etc., a combustion heat of alcohol, gas, etc. using a platinum catalyst, and a method of directly or indirectly using other heat source are used.

[0016]

[Examples] Hereinafter, the present invention will be described more specifically with reference to Examples and Test Examples. FIG. 1 shows a specific example of the drug vaporizer according to the present invention. The drug vaporizer 1 comprises a drug containing body 2 containing a drug and a container 3 containing the drug containing body 2. The container 3 is composed of two members, an upper container 4 and a lower container 5, and peripheral side walls of these upper and lower containers are cut out so as to form an opening 6 when the containers are fitted and fixed together and assembled. ing. On the outer surface of the upper plate portion 8 of the upper container 4 which forms the upper plate of the container 3 and the bottom plate portion 9 of the lower container 5 which forms the bottom plate when assembled, a plurality of (4 in this example) protrusions are provided. The portion 7 is provided so as to project, and when it is placed on the heating element 11 of the heating device 10 as shown in FIG. 2, a space S is formed between the bottom plate portion 9 of the lower container 5 and the heating element 11. It is supposed to be done. Therefore, when heated and used in the state shown in FIG. 2, the bottom plate portion 9 of the lower container 5 and the space S between this and the heating element 11 form a soaking portion, and the chemical substance contained in the container 3 is contained. The body 2 is heated uniformly.

In the case of the container shown in FIG. 1, since the convex portions 7 are formed on the outer surfaces of the upper container 4 and the lower container 5, the container is placed on the heating element 11 with either side facing down. Even when placed, a space S is formed between the container 3 and the heating element 11. However, the convex portion 7 may be provided only on the outer surface of one of the upper container 4 and the lower container 5.
In this case, when the surface on which the convex portion 7 is formed is placed on the heating element 11 with the surface facing downward, a space S is formed between the container and the heating element in the same manner as described above, and the drug-containing body 2 The lower surface can be set to a lower heating temperature, and when the surface on which the convex portion is not formed is placed on the heating element 11 with the lower surface facing downward, the lower surface of the container 3 and the heating element 11 come into contact with each other, and the drug-containing body The lower surface of 2 can be set to a heating temperature higher than that in the above case, which is advantageous when a large amount of chemical evaporation is required at the start of heating and use. Further, as shown in FIG. 3, it is possible not to form a convex portion on the outer surface of either the upper container 12 or the lower container 13.

In the case of the container shown in FIGS. 1 to 3, no apparent gap is formed between the inner surface of the container and the drug-containing body in appearance. Therefore, the drug contained in the drug-containing body 2 evaporates mainly from the lower surface, which is the surface to be heated, moves to the lower side of the drug-containing body, and is evaporated to the outside through the opening 6. On the other hand, in the case of the embodiment shown in FIG. 4, a plurality of ribs 16 for supporting a drug containing body are provided on the inner surfaces of the upper container 14 and the lower container 15 so as to project the inner surface and the drug containing body 2. A gap X is formed between them, so that the drug evaporated by heating flows more smoothly toward the opening 6. Further, the gap X also forms a soaking part together with the bottom plate part of the lower container 15 when the drug-containing body is heated.
The gap X may be formed only on the inner surface side of one of the upper container 14 and the lower container 15. FIG. 5 shows a modified example of the container shown in FIG.
8 is different in that the number of convex portions 19 formed on the outer surface of 8 and the installation place are different, and the fitting positions of the upper container 17 and the lower container 18 are not the four corners but other positions (sides, etc.). .

The embodiment shown in FIG. 6 shows a modification of the embodiment shown in FIG. 4, and the ribs 16 are formed on the inner surfaces of the upper container 20 and the lower container 21 in the same manner. Vent holes 22 and 23 are formed in the central portions of the upper container 20 and the lower container 21, respectively, and a convex portion 24 is projectingly provided on the outer surface of each of the upper container 20 and the lower container 21. Also in this case, the ventilation holes 22, 2
3, the convex portion 24, and the rib 16 can be formed on only one of the upper container 20 and the lower container 21, respectively. By providing the vent holes 22 and 23, the drug-containing body 2
The vaporization of the drug from the container can be carried out more smoothly, and the vent hole 23 of the lower container 21 has a gap X between the drug-containing body 2 and the bottom plate part of the lower container 21, the bottom plate part of the lower container 21 and the space between it and the heating element. A double heat equalizing part is formed together with the space. In addition, the above-mentioned ventilation hole is provided in the upper container and / or the lower container.
It is not limited to the case of providing one piece, and a plurality of pieces may be provided.

FIG. 7 shows another embodiment, in which a plurality of ribs 27 are provided on the inner surfaces of the upper container 25 and the lower container 26, respectively, and the upper plates of the upper container 25 and the lower container 26 are respectively formed. A plurality of ventilation holes 28 are formed in the bottom portion and the bottom plate portion. In addition, the communication hole 3 is formed in the center of the drug-containing body 29.
0 is formed, on the other hand, a cylindrical engaging rib 31 that is inserted into the communication hole 30 is provided at the center of the inner surface of the upper container 25, and at the center of the inner surface of the lower container 26. A locking protrusion 32 that is fitted and inserted into the cylindrical engagement rib 31 is provided in a protruding manner, and a mushroom-shaped bulge 33 is provided at the tip of the locking protrusion 32.
Is formed to have a retaining structure. The number of communication holes 30, the engaging ribs 31, and the locking protrusions 32 of the drug-containing body 29 and the installation locations may be arbitrary.

FIG. 8 shows an embodiment in which the appearance is completely different from that of each of the above-mentioned embodiments. In the case of this embodiment, the container 34 is composed of a frame body, and vertically protrudes at a predetermined position around the frame body. A plurality of locking pieces 35 each having a hook portion 36 whose tip portion is bent inward are provided, and the drug-containing body 2 is held in the frame container 34 by the hook portions 36 of the locking pieces 35. ing.

On the other hand, FIG. 9 shows a modification of the embodiment shown in FIG. 7, in which the convex portions 39 are formed on the outer surfaces of the upper container 37 and the lower container 38, and ribs are formed on the inner surfaces thereof. In addition to not being provided, the fitting structure of the upper container 37 and the lower container 38 is slightly different. That is, in the case of this example, on the inner surface of the upper container 37, the engaging rib 40 having the fitting hole 41 is provided at a position corresponding to the central communication hole 44 of the drug containing body 43, and the lower container 38 is provided with the engaging rib 40. On the inner surface,
The engaging rib 40 is provided at a position corresponding to the engaging rib 40.
A locking protrusion 42 that fits into the fitting hole 41 is provided in a protruding manner, and the locking protrusion 42 is fitted into the fitting hole 41 to assemble the upper container 37 and the lower container 38.

FIG. 10 shows another embodiment, in which the upper container 45
Also, an opening 47 is formed substantially in the center of the lower container 46, and a communication hole 49 is also formed in the substantially center of the drug-containing body 48. The openings 47 and the communication holes 49 have a substantially concentric positional relationship. Have In the case of this example, the central hole formed by the opening 47 and the communication hole 49 is used for volatilization of the drug. In the case of each of the embodiments shown in FIGS. 1 to 6 and FIG. 10 described above, a conventionally known technique can be used for fixing the upper and lower containers, and various methods such as hook fitting, screw fixing, welding, and adhesion can be used. Can be used.

The effects of the present invention will be specifically described below by showing various test examples. Test Example 1 The center temperature of the heating plate of the heating element was set to 120 ° C, 140 ° C, 160
Various heating plates (24 and 24 ° C)
X 36 mm) on top of polyphenylene sulfite (hereinafter P
The lower container 13 (22 × 34) of FIG. 3 made of PS).
X 0.3 mm) is installed, and the surface temperature of the heating plate and the lower container 13
The surface temperature of the PPS plate on the drug-containing body side was measured with a thermocouple type surface thermometer. In addition, the temperature measurement part was set to the intersection of the diagonal lines, and the measurement was performed at room temperature of 25 ° C. Separately, a convex portion having a height of 0.5 mm was projected on the bottom surface of the lower container, a space was provided between the lower container and the heating plate, and the temperature was measured in the same state as in FIG. The results are shown in Table 1.

[Table 1]

As is clear from the results shown in Table 1, even when there is a difference of 60 ° C. between 120 ° C. and 180 ° C. in the temperature of the heating plate surface of the heating element, when the lower container is placed, the drug-containing body side The surface temperature has a difference of 47 ° C., and when a convex portion is provided on the bottom surface of the lower container to provide a space between the surface temperature and the heating plate, a difference of 27 ° C. is obtained. In this way, by providing a soaking section by the space between the bottom plate of the lower container itself and the heat generating plate, it is possible to reduce the variation in the temperature of the upper surface of the lower container (lower surface of the drug-containing body) due to the difference in temperature of the heating element. It is possible to stabilize the heating of the medicine.

Test Example 2 A lower container (24 × 36 mm, thickness t = 0.5 mm, 1 mm) made of polysulfone shown in FIG. 5 was placed on a heating plate of a heating element using a positive temperature coefficient thermistor of a commercially available heat-transpiration mosquito trap. , And 2m
m, no convex portion on the bottom surface of the lower container) was installed, and the temperature distribution of the surface of the heating plate and the surface temperature of the upper surface of the lower container on the side of the drug-containing body were examined by a thermocouple type surface thermometer. The results are shown in Table 2.
Shown in. In addition, the temperature measuring part was set at 5 points (see FIG. 11) that divide the diagonal line of 24 × 36 mm into 6 equal parts, and the temperature was measured at room temperature of 25 ° C. In addition, 0.3 mm, 0.
5mm, 1.0mm, and 1.5mm height projections are projected,
The temperature distribution was similarly examined in the case where the spaces having the above-mentioned intervals were provided between the heating plate and the heating plate. The results are also shown in Table 2. The temperature distribution of the lower container having a thickness of 2.0 mm is shown in FIG.

[Table 2]

As is clear from the results shown in Table 2 and FIG. 12, when the commercially available positive temperature coefficient thermistor (hereinafter referred to as PTC) is used, the heating plate surface temperature is the portion where the PTC is located (see FIG. 11). The measurement part 3) had the highest temperature, and the temperature became lower toward the end, and the temperature difference between the maximum temperature and the minimum temperature on the surface of the heat generating plate was 40 ° C. or more. However, when the lower container made of polysulfone (Fig. 5) is installed on the heating plate, the surface temperature of the drug-containing body side becomes lower than the surface temperature of the heating plate as a whole, and the temperature difference between the maximum temperature and the minimum temperature is considerably eased. The thicker the container, the smaller the temperature range. However, in order to obtain a uniform temperature distribution only with the thickness of the container, the container becomes extremely thick, which causes problems of size and cost.
However, by providing a space between the heating plate and the container, a uniform temperature distribution can be obtained without increasing the size of the container. In this case, the spatial distance is 0.5
mm or more is preferable, and 1.0 mm or more is more preferable. The above means can heat the drug-containing body uniformly at a constant temperature, and is considered to be very effective in evaporating the drug. Also, by combining the thickness of the container and the space distance,
Since the temperature to be uniformly maintained can be set arbitrarily, it is possible to heat the drugs having different thermal characteristics under the optimum conditions even if the same heating plate is used.

Test Example 3 The solid preparations of Examples 1 and 2 having the following formulations were incorporated in a polysulfone container having the shape shown in FIG. 2, and mounted on a device having a heating plate temperature of 165 ° C. to set the lower surface temperature of the drug-containing body to 120 ° C. It is heated and evaporated, and the insecticidal active ingredient volatilized every 3 hours is sucked and collected on silica gel, and this is repeated up to the 12th hour. The sample solution extracted with acetone for each is quantitatively analyzed by gas chromatography. went. Next, the drug-containing body after heat evaporation for 12 hours was extracted with acetone, and the active ingredient was quantitatively analyzed in the same manner. Further, as comparative examples, the commercially available mats A and B having the same active ingredient content were similarly heat-transpirationd to quantify the active ingredient. Further, the drug decomposition rate was calculated from the following formula based on the relationship between the charged amount and the drug recovery amount. The results of each are shown in Table 3 below.

[0029] Example 1 Comparative example 1 Calcium phosphate 200 mg Commercial product (A) Praletrin 10 mg (Praretrin 10 mg) Lower surface temperature of mat 120 ° C Lower surface temperature of mat 165 ° C Example 2 Comparative example 2 Anhydrous calcium hydrogen phosphate 500 mg Commercial product (B) d-allethrin 36 mg (d-allethrin 36 mg) Lower surface temperature of mat 120 ° C Lower surface temperature of mat 165 ° C

[Table 3]

As is clear from the results shown in Table 3, when the commercially available insecticidal mats (A) and (B) were volatilized with a commercially available mosquito repellent for heat evaporation, a large amount of chemicals volatilized at the initial stage. ,
In the latter half, the amount of volatilization is remarkably reduced, resulting in insufficient efficacy.
In addition, drug decomposition is remarkable, and about 30% is decomposed. On the other hand, when a polysulfin container holding the drug-containing body was installed in a commercially available mosquito repellent for heating and evaporation, the lower surface temperature of the drug-containing body was 120 ° C., and in the formulations of Examples 1 and 2, from the beginning of heating. Stable transpiration of the drug was obtained with little change in the amount of volatilization until the second half. Further, the drug decomposition rate is very low, and effective drug volatilization can be obtained.

Test Example 4 A container made of polyamide having the shape shown in FIG.
Attach it to a device at 50 ° C, and lower the temperature of the drug-containing body to about 110.
The temperature was adjusted to 0 ° C., heat evaporation was carried out, and the active ingredient volatilized every 12 hours was quantitatively analyzed by the same method as in Test Example 3 above. The results are shown in Table 4.

[0032] Example 3 Example 6 Calcium phosphate 3000mg Talc 1000mg d-allethrin 40 mg prarethrin 10 mg Antioxidant A 1mg Antioxidant B 0.2mg Example 4 Example 7 Calcium phosphate 3000mg Talc 1000mg d-Allethrin 160 mg Praletrin 40 mg Antioxidant A 4mg Antioxidant B 0.8mg Example 5 Example 8 Calcium phosphate 3000mg Talc 1000mg d-allethrin 280 mg pralethrin 70 mg Antioxidant A 7mg Antioxidant B 1.4mg   Antioxidant A: Tris- (3.5-di-t-butyl-4-hydroxybenzyl) ) -Isocyanurate (trade name IRGANOX 3114)   Antioxidant B: 1.6-hexanediol-bis [3- (3.5-di-t-butyl Cyl-4-hydroxyphenylpropionate] (trade name IRGANOX 25 9)

[Table 4] As is clear from the results shown in Table 4, in each of the examples, stable volatilization of the active ingredient was obtained over a long period of time, and the effective volatilization rate was high.

[Brief description of drawings]

FIG. 1 is a perspective view showing an embodiment of a chemical vaporizer of the present invention.

FIG. 2 is a schematic cross-sectional view showing a state in which the chemical vaporizer of FIG. 1 is placed on a heating element of a heating device, omitting an internal structure of the heating device.

FIG. 3 is a cross-sectional view showing another embodiment of the chemical vaporizer of the present invention.

FIG. 4 is a cross-sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 5 is a cross-sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 6 is a cross-sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 7 is a cross-sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 8 is a cross-sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 9 is a sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 10 is a cross-sectional view showing still another embodiment of the chemical vaporizer of the present invention.

FIG. 11 is a schematic diagram for explaining a temperature measurement unit in Test Example 2.

FIG. 12 is a graph showing a temperature distribution obtained in Test Example 2.

[Explanation of symbols]

1 ... Drug vaporizer, 2, 29, 43, 48 ... Drug-containing body,
3 ... Container, 4, 14, 17, 20, 25, 37, 45 ...
Upper container, 5, 13, 15, 18, 21, 21, 26, 38,
46 ... Lower container, 6, 47 ... Opening part, 7, 19, 24,
39 ... Convex part, 8 ... Upper plate part, 9 ... Bottom plate part, 10 ... Heating device, 11 ... Heating element, 16, 27 ... Rib, 22, 23 ... Vent hole, 30, 44, 49 ... Communication hole, 31, 40 ... Engaging ribs, 32, 42 ... Locking protrusions, 34 ... Frame container, 35 ... Locking pieces, 36 ... Hook portions.

─────────────────────────────────────────────────── ─── Continuation of the front page (56) References JP-A-51-51467 (JP, A) JP-A-53-121938 (JP, A) Actually open Shou-51-78276 (JP, U) Actual-open Sho-53- 142474 (JP, U) Actual development Sho 59-81372 (JP, U) (58) Fields investigated (Int.Cl. ⁷ , DB name) A01N 25/18 A01M 1/20 A61L 9/12

Claims (8)

(57) [Claims] 1. A drug vaporizer for long-term evaporation, which is used by being placed on a heating element, comprising a synthetic resin molding container having an opening, and a drug-containing body held inside the container. It is a chemical vaporizer with a small amount of top and bottom plates of the container.
A plurality of protrusions are provided on at least one outer surface, and / or
Is the drug on the inner surface of at least one of the top and bottom plates of the container.
A plurality of ribs for supporting the agent-containing body are provided so as to project the agent-containing body so that the distance between the agent-containing body and the heating element is 1 mm or more.
A body vaporizer for long-term evaporation characterized by being supported by a container . 2. The chemical vaporizer for long-term evaporation according to claim 1, wherein an opening is formed in the peripheral side wall of the container. 3. The chemical vaporizer for long-term evaporation according to claim 1, wherein vent holes are formed in at least one of the top plate and the bottom plate of the container. 4. The container comprises two members, an upper container and a lower container, which are assembled by fitting.
The chemical vaporizer for long-term evaporation according to any one of 3 above. 5. The long-transpiration agents transpiration body according to any one of the drug-containing body into at least one communicating claim holes are formed 3-4. 6. At least one engaging rib having a fitting hole is projected from the inner surface of one of the upper container and the lower container of the container at a position corresponding to the communication hole of the drug-containing body, and the other On the inner surface of the upper container or the lower container of the above, at the position corresponding to the engaging rib, a locking protrusion that fits in the fitting hole of the engaging rib is projected, and the locking protrusion is fitted. The chemical vaporizer for long-term evaporation according to claim 4 , wherein the upper container and the lower container are assembled by fitting the fitting holes. 7. A cylindrical shape in which a communication hole is formed in the center of the drug-containing body, and the communication hole is inserted into the center of one inner surface of one of the upper plate forming the upper container and the bottom plate forming the lower container. The engaging ribs are provided so as to project, and at the center portion of the inner surface of the other upper plate or bottom plate, the engaging protrusions that are fitted into the cylindrical engaging ribs are provided so as to bulge at the tips of the engaging protrusions. The chemical vaporizer for long-term evaporation according to claim 6 , wherein a portion is formed. 8. The container is composed of a frame, and a plurality of locking pieces having hook portions projecting vertically and having a tip end bent inward are provided at predetermined positions around the frame, and the locking pieces are provided. The drug evaporating body for long-term evaporation according to claim 1, wherein the drug-containing body is held by the frame body.